ChronicleBio
ChronicleBio is a venture-backed techbio startup building an AI-driven multi-omic data platform to stratify patients with complex neuroimmune disorders (ME/CFS, Long COVID, POTS) by disease mechanism, supporting biomarker discovery, drug repurposing, and precision therapeutic development for biopharma partners.
- Company typePrivate
- Founded2025
- HeadquartersMenlo Park, United States
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What ChronicleBio does
ChronicleBio is a privately held techbio startup founded in 2025 and headquartered in the San Francisco Bay Area (Menlo Park), building an AI-driven multi-omic data platform aimed at accelerating diagnosis and treatment for complex neuroimmune disorders including ME/CFS, Long COVID, POTS, migraine, MCAS, Ehlers-Danlos Syndrome, Sjögren's, persistent Lyme, and fibromyalgia. The company's core technology is a multi-omic endotype framework that integrates whole-genome sequencing, epigenetics, RNA sequencing, immune profiling, proteomics, and metabolomics to stratify patients by disease mechanism before treatment begins, addressing the systemic failure of chronic disease drug pipelines that historically lack mechanism-anchored patient selection. The platform is fed by the Chronicle I Study and Chronicle Connect participant app, which collect longitudinal clinical data, wearable telemetry, symptom logs, and biospecimens (blood, urine, cheek swab) through a four-clinic partner network in Texas and Utah, supplemented by access to the Solve M.E. Solve Together dataset (the largest ME/CFS/Long COVID patient-reported dataset in the U.S.) via a five-party research consortium with Solve M.E., the Brain Inflammation Collaborative, the Complex Disorders Alliance, and CareEvolution.
The intended revenue model combines biopharmaceutical development (biomarker discovery, patient stratification, and precision therapeutic development for licensing or royalty economics) with data and research services to pharmaceutical companies, biotech firms, and research organizations. Leadership combines commercial-tech and biomedical depth: Co-Founder & CEO Rohit Gupta (formerly Stanford and UCSF biobanking), Co-Founder & Director Fidji Simo (Instacart CEO, incoming CEO of OpenAI's applications division), Co-Founder & Executive Chairman Rishi Reddy (Tarsadia Investments), CSO Dr. John Mumm (founder of Deka Biosciences, founding member of ARMO BioSciences acquired by Eli Lilly for $1.6B), and Head of Platform Dr. Yambazi Banda (Oxford Rhodes Scholar, former UCSF and Ancestry.com genomics leader). The company is sub-50 employees, venture-backed by Wisdom Ventures, and is at platform-buildout and data-acquisition stage rather than commercial revenue.
ChronicleBio firmographics
Firmographics- Name
- ChronicleBio
- Legal name
- ChronicleBio
- Website
- https://chroniclebio.com
- Company type
- Private
- Founded year
- 2025
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- ChronicleBio is a venture-backed techbio startup building an AI-driven multi-omic data platform to stratify patients with complex neuroimmune disorders (ME/CFS, Long COVID, POTS) by disease mechanism, supporting biomarker discovery, drug repurposing, and precision therapeutic development for biopharma partners.
- Ownership category
- akta.pro rank
ChronicleBio industry classification
Industry- Product category
- Precision Medicine Data Platform
- NAICS
- Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Medical Laboratories (8071)
- akta.pro primary industry
- Bioinformatics & Multi-omics Analysis Software (HLAGAJAD)
- akta.pro secondary industries
- Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics) (HLAAAMAJ), Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI), Prognostic & Risk Stratification Biomarkers (disease progression, recurrence risk) (HLAAAMAF)
Keywords
Where ChronicleBio is headquartered
LocationHeadquarters
- HQ city
- Menlo Park
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
ChronicleBio business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Biopharmaceutical Development: ChronicleBio is developing therapeutics through biomarker discovery, patient stratification, and precision therapeutic development for neuroimmune conditions. The company applies patient data to fuel transformative clinical trials and identify which clinical-stage drugs might work for specific patient subgroups.
- Data & Research Services: The company provides data services to research partners, pharmaceutical companies, and healthcare organizations through its multi-omic analysis platform, biomarker discovery capabilities, and patient stratification insights.
Go-to-market motion1 record
Distribution channels4 records
Marketing channels5 records
ChronicleBio product offering
Product offeringCore offering
ChronicleBio builds a multi-omic endotype framework integrating whole-genome sequencing, epigenetics, RNA sequencing, immune profiling, proteomics, and metabolomics to identify biologically coherent patient subgroups before treatment. The company combines clinical and biological data, large biological models trained on native human biology, and longitudinal multimodal patient data into an 'Internet of Biology' data ecosystem to power biomarker discovery, drug repurposing, and new diagnostics for complex neuroimmune conditions.
Product overview
ChronicleBio is a data-driven techbio company building the 'Internet of Biology' — a multi-omic endotype framework that integrates whole-genome sequencing, epigenetics, RNA sequencing, immune profiling, proteomics, and metabolomics data to stratify patients by disease mechanism before treatment begins. The core Multi-Omic Endotype Framework powers biomarker discovery, drug repurposing, and new diagnostics. The Chronicle I Study serves as the primary data collection vehicle, sourcing rich longitudinal multimodal clinical and biological data through the Chronicle Connect participant platform, creating an interconnected data ecosystem that trains AI models on native human biology to unlock novel therapeutic insights for neuroimmune conditions.
Differentiator
Problem solved
Functional benefit
Brands
- Chronicle I: A research study part of Chronicle Connect, where participants contribute health data, biospecimens, and lived experience to accelerate breakthroughs for complex chronic conditions including ME/CFS, Long COVID, POTS, Migraine Disorders, MCAS, Ehlers-Danlos Syndrome, Sjögren's, Persistent Lyme, and Fibromyalgia.
Products and services
- Chronicle I Study A research study enrolling patients with complex chronic conditions (ME/CFS, Long COVID, POTS, Migraine Disorders, MCAS, Ehlers-Danlos Syndrome, Sjögren's, Persistent Lyme, Fibromyalgia) to contribute health data, biospecimens, and lived experience that power biomarker discovery, drug repurposing, and new diagnostics.
Quantifiable outcome
- Potential to transform 20% response rates into 70% response rates with right biomarker stratification
Companies that use ChronicleBio
Customer profileNamed customers8 records
Segments4 records
Ideal customer profiles3 records
ChronicleBio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature4 records
ChronicleBio partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core.
- Solve M.E.coreSolve M.E., a national nonprofit dedicated to making ME/CFS, Long COVID, and IACCIs widely understood, diagnosable, and treatable, has collected patient-reported data through the Solve Together platform since 2010. This partnership allows ChronicleBio to receive patient data to deepen insights and fuel transformative clinical trials. The Solve Together platform is the largest database of its kind in the U.S. and contains pre- and post-COVID-19 health information.
- Brain Inflammation Collaborative (BIC)coreThe Brain Inflammation Collaborative, a patient-centered nonprofit, took over management of the Solve Together platform and will expand it to include pediatric populations, additional diagnoses, and assessments on links between brain inflammation and mental health. The goal is more diverse and inclusive research across rural, marginalized, and underserved communities.
- Complex Disorders AlliancecoreThe Complex Disorders Alliance, a patient-founded nonprofit that drives the development of diagnostics and treatments, receives data from Solve M.E. as part of the collaboration. The partnership aims to unite, pool data, insights, and expertise to drive breakthroughs that put patients first.
- CareEvolutioncoreCareEvolution created the Solve Together dynamic platform that allows users to track symptoms, sync wearables, generate reports for providers, and opt into clinical studies. The platform serves as the technical backbone for the research collaboration and is the largest database of its kind in the U.S.
- Continental HospitalscorePartner clinic for biobank sample collection including blood, urine, or cheek swab. The partnership enables ChronicleBio to source biospecimens for its multi-omics analysis platform.
- Bateman Horne CentercorePartner clinic for biobank sample collection and clinical research coordination. The center is dedicated to improving care for patients with complex chronic conditions.
- FourPeaks HealthcorePartner clinic for biobank sample collection and clinical research coordination. Serves as a clinical site for ChronicleBio's research activities.
- The Heartbeat ClinicscorePartner clinic for biobank sample collection and clinical research coordination. Specialized clinic supporting ChronicleBio's participant engagement efforts.
Scale indicators4 records
Recent moves6 records
Expansion highlights6 records
ChronicleBio competitors and assessment
Company assessmentDirect peers
- Insitro: AI-driven drug discovery company combining machine learning with high-throughput biology and multi-omic data to identify therapeutic targets, closely aligned with ChronicleBio's AI-on-native-biology approach.
- Owkin: Biomedical AI company that builds multi-omic patient stratification models and partners with pharma to accelerate drug development, sharing the 'AI + multi-omics + pharma BD' model.
- nference: Biomedical AI platform that synthesizes multi-omic and clinical data to surface therapeutic insights and accelerate pharma R&D, a directly comparable multi-omic AI platform serving pharma partners.
- Scipher Medicine: Network-medicine platform using molecular data and AI to match patients with effective therapies for complex autoimmune and inflammatory diseases, directly comparable to ChronicleBio's multi-omic stratification thesis for complex conditions.
Broad incumbents
- Tempus AI: Established multi-omic data platform and AI company serving oncology and increasingly other disease areas; a broader incumbent operating at scale with pharma partnerships that ChronicleBio aspires to compete with.
- Foundation Medicine (Roche): Genomic profiling leader (now owned by Roche) that pioneered biomarker-driven treatment selection via large-scale molecular data; represents the gold standard for multi-omic-to-treatment pipelines ChronicleBio seeks to replicate in neuroimmune indications.
- Recursion Pharmaceuticals: Public AI-driven drug discovery company combining high-throughput biology with foundation models; a larger and more mature comparable in the techbio category, though with broader indication scope.
- Generate:Biomedicines: Generative AI biology company building foundation models on biological data to design novel therapeutics, comparable in its AI-on-biology orientation though with a different downstream product strategy.
Others
- CareEvolution: Health data platform that powers the Solve Together infrastructure ChronicleBio now uses; relevant as the enabling technology partner and adjacent ecosystem participant.
- PatientsLikeMe: Patient-driven health data platform with deep roots in chronic disease communities; comparable for its community-led approach to generating longitudinal patient-reported data, a model ChronicleBio adapts for the multi-omic era.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
ChronicleBio social profiles
Digital presenceChronicleBio financial estimates
Financial estimateRevenue estimate
Valuation estimate
ChronicleBio leadership team
Management profileNumber of profiles
Profiles6 records
ChronicleBio funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ChronicleBio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ChronicleBio
What does ChronicleBio do?
ChronicleBio builds a multi-omic endotype framework integrating whole-genome sequencing, epigenetics, RNA sequencing, immune profiling, proteomics, and metabolomics to identify biologically coherent patient subgroups before treatment. The company combines clinical and biological data, large biological models trained on native human biology, and longitudinal multimodal patient data into an 'Internet of Biology' data ecosystem to power biomarker discovery, drug repurposing, and new diagnostics for complex neuroimmune conditions.
Is ChronicleBio a public or private company?
ChronicleBio is a private company. It is classified as venture growth investor backed and is currently operating.
When was ChronicleBio founded?
ChronicleBio was founded in 2025. It employs 11 to 50 people.
Where is ChronicleBio based?
ChronicleBio is headquartered in Menlo Park, United States, in the North America region.
How does ChronicleBio make money?
Two revenue lines are on record. Biopharmaceutical Development is the primary driver. The others are data & Research Services.
Who are ChronicleBio's main competitors?
Direct peers on record are Insitro, Owkin, nference and Scipher Medicine. Broad incumbents are Tempus AI, Foundation Medicine (Roche), Recursion Pharmaceuticals and Generate:Biomedicines. Others are CareEvolution and PatientsLikeMe.
Does ChronicleBio have an API?
No public API is recorded for ChronicleBio.
What industry is ChronicleBio in?
ChronicleBio's product category is Precision Medicine Data Platform. Its primary akta.pro industry code is HLAGAJAD, Bioinformatics & Multi-omics Analysis Software, with a secondary code of HLAAAMAJ, Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics). Its NAICS code is 621511 and its SIC code is 8071.